Gerik-Celebi Hamide Betul, Aydin Hilal, Bolat Hilmi, Unsel-Bolat Gul
Department of Medical Genetics, Balıkesir Ataturk City Hospital, Balıkesir, Turkey.
Department of Pediatrics, Division of Child Neurology, Balıkesir University Faculty of Medicine, Balıkesir, Turkey.
Mol Syndromol. 2023 Jun;14(3):208-218. doi: 10.1159/000529018. Epub 2023 Mar 14.
Global developmental delay (DD), intellectual disability (ID), and autism spectrum disorder (ASD) are mainly evaluated under the neurodevelopmental disorder framework. In this study, we aimed to determine the genetic diagnosis yield using step-by-step genetic analysis in 38 patients with unexplained ID/DD and/or ASD.
In 38 cases (27 male, 11 female) with unexplained ID/DD and/or ASD, chromosomal microarray (CMA) analysis, clinical exome sequencing (CES), and whole-exome sequencing (WES) analysis were applied, respectively.
We found a diagnostic rate of only CMA analysis as 21% (8/38) presenting 8 pathogenic and likely pathogenic CNVs. The rate of patients diagnosed with CES/WES methods was 32.2% (10/31). When all pathogenic and likely pathogenic variants were evaluated, the diagnosis rate was 44.7% (17/38). A dual diagnosis was obtained in a case with 16p11.2 microduplication and de novo SNV. We identified eight novel variants: (c.787C>G), (c.334-2A>G), (c.2051_2052del), (c.12064C>T), (c.13187G>A), (c.1189T>C), (c.328_330dup), and (c.17G>A).
We present diagnostic rates of a complementary approach to genetic analysis (CMA, CES, and WES). The combined use of genetic analysis methods in unexplained ID/DD and/or ASD cases has contributed significantly to diagnosis rates. Also, we present detailed clinical characteristics to improve genotype-phenotype correlation in the literature for rare and novel variants.
全球发育迟缓(DD)、智力残疾(ID)和自闭症谱系障碍(ASD)主要在神经发育障碍框架下进行评估。在本研究中,我们旨在通过逐步基因分析确定38例不明原因的ID/DD和/或ASD患者的基因诊断率。
对38例(27例男性,11例女性)不明原因的ID/DD和/或ASD患者分别进行染色体微阵列(CMA)分析、临床外显子组测序(CES)和全外显子组测序(WES)分析。
我们发现仅CMA分析的诊断率为21%(8/38),呈现8个致病性和可能致病性的拷贝数变异(CNV)。通过CES/WES方法诊断的患者比例为32.2%(10/31)。当评估所有致病性和可能致病性变异时,诊断率为44.7%(17/38)。在1例16p11.2微重复和新发单核苷酸变异(SNV)的病例中获得了双重诊断。我们鉴定出8个新变异:(c.787C>G)、(c.334-2A>G)、(c.2051_2052del)、(c.12064C>T)、(c.13187G>A)、(c.1189T>C)、(c.328_330dup)和(c.17G>A)。
我们展示了基因分析(CMA、CES和WES)互补方法的诊断率。在不明原因的ID/DD和/或ASD病例中联合使用基因分析方法显著提高了诊断率。此外,我们还展示了详细的临床特征,以改善文献中罕见和新变异的基因型-表型相关性。